

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE
03 FEB 13 AM 11:20

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name The Waldmann Group			
2. Address <input type="checkbox"/> Check if different than previously reported 1201 Pennsylvania Ave., NW, Suite 300, Washington, DC 20004			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Daniel Waldmann	Telephone (202) 661-4788	E-mail (optional)	5. Senate ID # 7003E
7. Client Name <input type="checkbox"/> Self Johnson & Johnson			6. House ID # 35799

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>40,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of method.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>
---	---

Signature _____

Printed Name and Title _____

Daniel Waldmann, Managing Director

Registrant Name The Waldmann Group Client Name Johnson & Johnson

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

HR 3580, The Medical Device Amendments of 2001.
HR 5651, The Medical Device User Fee and Modernization Act.
Reprocessing of single use medical devices.
Changes to the FDA generic drug approval process.
Reimportation of prescription drugs.
S 1274/HR 3431, STOP Stroke Act.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives, Senate.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Daniel Waldmann	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Daniel R. Waldmann* Date 02/06/2003

Printed Name and Title Daniel Waldmann, Managing Director

Registrant Name The Waldmann Group Client Name Johnson & Johnson

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare reimbursement for medical devices and prescription drugs in general.
Medicare coverage and reimbursement for self-injectable drugs.
Medicare reimbursement for drugs under the hospital outpatient prospective payment system.
Reform of average wholesale price (AWP) methodology.
HR 4954, Medicare Modernization and Prescription Drug Act of 2002.
S 2/S 2729, 21st Century Medicare Act.
S 2625, Medicare Outpatient Prescription Drug Act of 2002.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives, Senate.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Daniel Waldmann	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Daniel R. Waldmann* Date 02/06/2003

Printed Name and Title Daniel Waldmann, Managing Director

